HeartSciences Inc. (HSCS)
| Market Cap | 6.34M +75.0% |
| Revenue (ttm) | 8,669 -76.6% |
| Net Income | -8.49M |
| EPS | -4.03 |
| Shares Out | 3.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,714 |
| Open | 1.910 |
| Previous Close | 1.940 |
| Day's Range | 1.900 - 2.000 |
| 52-Week Range | 1.800 - 6.470 |
| Beta | 2.04 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+302.21%) |
| Earnings Date | Mar 16, 2026 |
About HSCS
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVist... [Read more]
Financial Performance
In fiscal year 2025, HeartSciences's revenue was $4,350, a decrease of -76.61% compared to the previous year's $18,600. Losses were -$8.77 million, 32.7% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for HSCS stock is "Strong Buy" and the 12-month stock price target is $8.0.
News
HeartSciences signs MyoVista commercial agreement with St. Vincent Health
HeartSciences (HSCS) announced that it has signed a commercial agreement with St. Vincent Health to deploy the MyoVista Insights platform.
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
Agreement with St. Vincent Health marks HeartSciences' transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College...
HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) a healthcare information technology (“HIT”) company focused on advancing e...
HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advanci...
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancin...
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advan...
HeartSciences announces UWE adopted MyoVista Insights, MyoVista wavECG
HeartSciences (HSCS) announced that the University of the West of England, UWE, has adopted the Company’s MyoVista Insights platform and MyoVista wavECG device as its exclusive ECG technologies to est...
University of West England Adopts HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electroca...
HeartSciences MyoVista Insights selected by Cibolo Rural Health Networks
HeartSciences (HSCS) announced that Cibolo Rural Health Networks has selected MyoVista Insights as its endorsed ECG management platform for independent hospitals within its high-value networks. This c...
Cibolo Health Designates HeartSciences' MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing...
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electroc...
HeartSciences announces FDA 510(k) submission for MyoVista wavECG
HeartSciences (HSCS) submitted its MyoVista wavECG device to the U.S. Food and Drug Administration for 510(k) premarket clearance. The MyoVista wavECG device is designed to provide conventional ECG fu...
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of...
HeartSciences announces commercial release of MyoVista Insights version 1.1
HeartSciences (HSCS) announced the commercial release of MyoVista Insights version 1.1, a major update that is built to provide the most usable ECG system and enhances clinical interpretation capabili...
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
Southlake, TX, Dec. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ...
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company tran...
HeartSciences Announces Conference Participation and Investor Webinar
Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85 Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company trans...
HeartSciences recesives FDA BDD for Aortic Stenosis ECG algorithm
HeartSciences (HSCS) announced that the U.S. Food and Drug Administration has granted Breakthrough Device designationless than BDD, for its Aortic Stenosis ECG algorithm. The algorithm would offer a n...
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Southlake, TX, June 04, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focus...
HeartSciences announces grant by USPTO for ECG assessment of heart function
HeartSciences (HSCS) announced the grant by the United States Patent and Trademark Office, USPTO, of a foundational patent covering the estimation of echocardiography parameters indicative of heart fu...
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value
Southlake, TX, June 03, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focus...
HeartSciences signs first MyoVista Insights platform customer
HeartSciences (HSCS) announced the signing of its first commercial customer for the MyoVista Insights platform: Westcliffe Health Innovations, based in the United Kingdom. This milestone follows the r...
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”)-powered medical technology company focuse...
HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc . (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on tran...